Novo Nordisk has had a difficult year: a tumbling stock price resulting in the biggest leadership shakeup in the company's ...

¿Por qué es importante? Se trata del primer medicamento GLP-1 de forma oral que ya está aprobado oficialmente en Estados ...

Investing.com - Las acciones de Novo Nordisk subieron el martes después de que la compañía obtuviera la aprobación estadounidense para su píldora de pérdida de peso GLP-1, marcando la primera vez que ...

Danish drugmaker Novo Nordisk A/S was at the forefront of the weight-loss injection boom as people discovered that its ...

Novo Nordisk’s oral Wegovy wins FDA approval, outperforming rivals in weight loss. Discover why NVO stock is undervalued now.

Bidding to buy metabolic medicines biotech Metsera in September came down to two pharmaceutical giants, with Novo Nordisk’s higher offer losing out to Pfizer’s $4.9 billion price in part due to ...

Novo Nordisk A/S secures FDA nod for oral Wegovy, expanding obesity treatment options. Click for how oral GLP-1 therapies ...

Novo Nordisk is set to lay off roughly 9,000 employees across its global workforce of 78,400 as part of a newly launched restructuring initiative. In a Sept. 10 press release, the Danish ...

The U.S. Food and Drug Administration on Dec. 22 approved a pill version of Novo Nordisk’s weight-loss drug Wegovy.

CHONGQING, CHINA - SEPTEMBER 10: In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. The maker of Wegovy and Ozempic, ...

The maker of the blockbuster weight loss and diabetes drugs Wegovy and Ozempic have cut the prices for most versions of these medications. Novo Nordisk dropped the price for injectable Wegovy and ...